BIOBANK acquired by IK PARTNERS
Context
This transaction structurally constitutes a tertiary leveraged buyout, marking a significant reorganization of the target's capital structure. The incoming pan-European financial sponsor successfully preempted a highly competitive auction process orchestrated by a specialized investment bank, decisively securing a majority controlling stake. Crucially, the operation features substantial reinvestments from both historical private equity partners and the entire executive management team, ensuring total long-term strategic alignment. The capital structure is completed by a bespoke unitranche debt facility currently under final negotiation. The primary strategic rationale underpinning this renewed financial partnership is to massively accelerate the company's international rollout. The explicit roadmap mandates robust external growth through targeted acquisitions and the establishment of new distributor partnerships across specific neighboring European countries, aiming to swiftly replicate its domestic dominance on a continental scale.
BIOBANK, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Biobank is a specialized medtech company and the undisputed domestic market leader in providing bone allografts to orthopedic surgeons. These critical grafts are sustainably sourced from living donors during specific surgical procedures. The company boasts a highly resilient and exceptionally secure operational risk profile. Over recent years, the firm has successfully transformed from a localized entity into a robust international player, establishing a strong regulatory, clinical, and marketing foundation. Its superior allograft technology is steadily replacing traditional alternative techniques across the medical field. Following a successful historical acquisition of its Swiss distributor, the enterprise is strategically positioned to leverage its advanced technological edge to continuously expand and ultimately capture the premier leadership position across the entire European orthopedic grafting market.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2025 | PATRICIA INDUSTRIES | NOVA BIOMEDICAL | UNITED STATES | Diagnostic Equipment |
| 07/2025 | BC PARTNERS | BIOGARAN | FRANCE | Pharma & Biotech |
| 05/2025 | OTTOBOCK | MATTON ORTHOMEDI | BELGIUM | Implants & Prosthetics |
| 04/2025 | NORGINE | THERAVIA | FRANCE | Generics / Labs |
| 04/2025 | IK PARTNERS | STERIMED | FRANCE | Medical Consumables |
| 04/2025 | INSTITUT MERIEUX / ARCHIMED | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 04/2025 | CINVEN | NUTRISENS | FRANCE | Nutrition & Dietary Supplements |
| 04/2025 | PATIENT SQUARE CAPITAL | PATTERSON COMPANIES | UNITED STATES | Medical Consumables |
| 03/2025 | NUTRISENS | PRODIET | BRAZIL | Nutrition & Dietary Supplements |
| 03/2025 | SIPAREX | LABORATOIRE POLIDIS | FRANCE | Medical Consumables |
REFERENCES
Valuation range: EV 50M - 150M EUR
Revenue range: 10M - 30M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIOBANK by IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: ik partners